Atlas Trials

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Clinical trial NCT01499251 · TERMINATED

Trial details

NCT number
NCT01499251
Sponsor
Actelion
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Glioblastoma
Start date
2012-01-01
Primary completion
2016-01-01
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.